Skip to main content
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC — Investor Relations & Filings

Ticker · CGTX ISIN · US19243B1026 US Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2022-11-16 Director's Dealing
Country US United States of America
Listing US CGTX

About COGNITION THERAPEUTICS INC

https://cogrx.com/

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company that discovers and develops oral, small-molecule therapeutics for neurodegenerative disorders. The company's primary focus is on conditions such as Alzheimer's disease and Dementia with Lewy Bodies (DLB). Its therapeutic approach is centered on developing medications designed to target and modulate key cellular damage response mechanisms. By aiming to rescue trafficking deficits and restore normal cellular housekeeping functions, the company seeks to protect neurons, improve synaptic health, and ultimately address the cognitive decline associated with these diseases.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2022-11-16 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-14 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock, announcements of financial results via press releases, and other events such as pricing of the offering. There are no full financial statements or detailed financial analysis included, only references to press releases and agreements. The primary focus is on financing activities and capital raising through the public offering. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length is 6418 characters, which is consistent with a detailed 8-K filing but not a full annual or quarterly report. Hence, the classification is CAP with high confidence.
2022-11-14 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) under a Registration Statement No. 333-268228. It describes an offering of 5,000,000 shares of common stock, including pricing, underwriting details, risk factors, use of proceeds, and extensive business and financial information about the company. The document is not a financial report like an annual or quarterly report, nor is it a management discussion or earnings release. It is a formal offering document related to capital raising through a public stock offering. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-11-14 English
Regulatory Filings 2022
Regulatory Filings
2022-11-10 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1 filed by Cognition Therapeutics, Inc. It is a request for acceleration of the effective date of the Registration Statement under Rule 461 of the Securities Act of 1933. The letter also mentions compliance with Rule 460 and Rule 15c2-8. The content is related to the process of securities registration and underwriting, not a financial report or earnings release. The document length is short (2078 characters) and it is a formal correspondence related to regulatory filing procedures rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2022-11-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.